Postconditioning with levosimendan reduces the infarct size involving the PI3K pathway and KATP-channel activation but is independent of PDE-III inhibition

Basic Research in Cardiology

Volumn 105, Issue 2, 2010, Pages 155-167

  Hönisch, Antje ^a   Theuring, Norman ^a   Ebner, Bernd ^a   Wagner, Claudia ^a   Strasser, Ruth H ^a   Weinbrenner, Christof ^a  

^a University Heart Center Dresden   (Germany)

Author keywords

ATP dependent K + channel; Infarction; Levosimendan; PI3K pathway; Postconditioning

Indexed keywords

5 HYDROXYDECANOIC ACID; ADENOSINE TRIPHOSPHATE SENSITIVE POTASSIUM CHANNEL; ENOXIMONE; GLYCOGEN SYNTHASE KINASE 3BETA; LEVOSIMENDAN; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; WORTMANNIN; CARDIOTONIC AGENT; HYDRAZONE DERIVATIVE; PHOSPHODIESTERASE III; PHOSPHODIESTERASE INHIBITOR; PYRIDAZINE DERIVATIVE; SIMENDAN;

ACUTE HEART INFARCTION; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTERIAL PRESSURE; ARTICLE; CONTROLLED STUDY; DRUG ACTIVITY; GENE ACTIVATION; HEART INFARCTION SIZE; HEART PROTECTION; HEART RATE; HEMODYNAMICS; IMMUNOREACTIVITY; IN VIVO STUDY; LEFT CORONARY ARTERY; MALE; MORTALITY; NONHUMAN; PROTEIN PHOSPHORYLATION; RAT; REPERFUSION INJURY; SIGNAL TRANSDUCTION; ANIMAL; DRUG ANTAGONISM; HEART MUSCLE; IMMUNOBLOTTING; METABOLISM; PATHOLOGY; WISTAR RAT;

1-PHOSPHATIDYLINOSITOL 3-KINASE; ANIMALS; CARDIOTONIC AGENTS; CYCLIC NUCLEOTIDE PHOSPHODIESTERASES, TYPE 3; ENOXIMONE; HEMODYNAMICS; HYDRAZONES; IMMUNOBLOTTING; KATP CHANNELS; MALE; MYOCARDIAL REPERFUSION INJURY; MYOCARDIUM; PHOSPHODIESTERASE INHIBITORS; PYRIDAZINES; RATS; RATS, WISTAR; SIGNAL TRANSDUCTION;

EID: 77950353079     PISSN: 03008428     EISSN: 14351803     Source Type: Journal    
DOI: 10.1007/s00395-009-0064-9     Document Type: Article

References (65)

1. Archan S, Toller W (2008) Levosimendan: current status and future prospects. Curr Opin Anaesthesiol 21: 78-84
2. Cohen MV, Yang XM, Downey JM (2008) Acidosis, oxygen, and interference with mitochondrial permeability transition pore formation in the early minutes of reperfusion are critical to postconditioning's success. Basic Res Cardiol 103: 464-471
3. 2 inhibit the mitochondrial permeability transition, J Biol Chem 281: 20801-20808
4. Darling CE, Jiang R, Maynard M., Whittaker P, Vinten-Johansen J, Przyklenk K (2005) Postconditioning via stuttering reperfusion limits myocardial infarct size in rabbit hearts: role of ERK1/2. Am J Physiol Heart Circ Physiol 289: H1618-H1626
5. Das B, Sarkar C (2007) Pharmacological preconditioning by levosimendan is mediated by inducible nitric oxide synthase and mitochondrial KATP channel activation in the in vivo anesthetized rabbit heart model. Vase Pharmacol 47: 248-256
6. du Toit EF, Genis A, Opie LH, Pollesello P, Lochner A (2008) A role for the RISK pathway and K(ATP) channels in pre- and postconditioning induced by levosimendan in the isolated guinea pig heart. Br J Pharmacol 154: 41-50
7. du Toit EF, Muller CA, McCarthy J, Opie LH (1999) Levosimendan: effects of a calcium sensitizer on function and arrhythmias and cyclic nucleotide levels during ischemia/reperfusion in the Langendorff-perfused guinea pig heart. J Pharmacol Exp Ther 290: 505-514
8. Edes I, Kiss E, Kitada Y, Powers FM, Papp JG, Kranias EG, Solaro RJ (1995) Effects of levosimendan, a cardiotonic agent targeted to troponin C, on cardiac function and on phosphorylation and Ca2+ sensitivity of cardiac myofibrils and sarcoplasmic reticulum in guinea pig heart. Circ Res 77: 107-113
9. Feng J, Lucchinetti E, Ahuja P, Pasch T, Perriard JC, Zaugg M (2005) Isoflurane postconditioning prevents opening of the mitochondrial permeability transition pore through inhibition of glycogen synthase kinase 3beta. Anesthesiology 103: 987-995
10. Follath F, Cleland JG, Just H, Papp JG, Scholz H, Peuhkurinen K, Harjola VP, Mitrovic V, Abdalla M, Sandell EP, Lehtonen L (2002) Efficacy and safety of intravenous levosimendan compared with dobutamine in severe low-output heart failure (the LIDO study): a randomised double-blind trial. Lancet 360: 196-202
11. Fuhrmann JT, Schmeisser A, Schulze MR, Wunderlich C, Schoen SP, Rauwolf T, Weinbrenner C, Strasser RH (2008) Levosimendan is superior to enoximone in refractory cardiogenic shock complicating acute myocardial infarction. Crit Care Med 36: 2257-2266
12. Fukasawa M, Nishida H, Sato T, Miyazaki M, Nakaya H (2008) Cilostazol, a phosphodiesterase type 3 inhibitor, reduces infarct size via activation of mitochondrial Ca2+-activated K+ channels in rabbit hearts. J Pharmacol Exp Ther 326: 100-104
13. Garlid KD, Dos Santos P, Xie ZJ, Costa AD, Paucek P (2003) Mitochondrial potassium transport: the role of the mitochondrial ATP-sensitive K(+) channel in cardiac function and cardioprotection. Biochim Biophys Acta 1606: 1-21
14. Gomez L, Paillard M, Thibault H, Derumeaux G, Ovize M (2008) Inhibition of GSK3beta by postconditioning is required to prevent opening of the mitochondrial permeability transition pore during reperfusion. Circulation 117: 2761-2768
15. Gross ER, Hsu AK, Gross GJ (2008) Delayed cardioprotection afforded by the glycogen synthase kinase 3 inhibitor SB-216763 occurs via a KATP- and MPTP-dependent mechanism at reperfusion. Am J Physiol Heart Circ Physiol 294: H1497-H1500
16. Gross GJ, Auchampach JA (1992) Blockade of ATP-sensitive potassium channels prevents myocardial preconditioning in dogs. Circ Res 70: 223-233
17. Haikala H, Kaivola J, Nissinen E, Wall P, Levijoki J, Linden IB (1995) Cardiac troponin C as a target protein for a novel calcium sensitizing drug, levosimendan. J Mol Cell Cardiol 27: 1859-1866
18. Haikala H, Nissinen E, Etemadzadeh E, Levijoki J, Linden IB (1995) Troponin C-mediated calcium sensitization induced by levosimendan does not impair relaxation. J Cardiovasc Pharmacol 25: 794-801
19. Hasenfuss G, Holubarsch C, Heiss HW, Meinertz T, Bonzel T, Wais U, Lehmann M, Just H (1989) Myocardial energetics in patients with dilated cardiomyopathy. Influence of nitroprusside and enoximone. Circulation 80: 51-64
20. Hausenloy DJ, Mocanu MM, Yellon DM (2004) Cross-talk between the survival kinases during early reperfusion: its contribution to ischemic preconditioning. Cardiovasc Res 63: 305-312
21. Hausenloy DJ, Ong SB, Yellon DM (2009) The mitochondrial permeability transition pore as a target for preconditioning and postconditioning. Basic Res Cardiol 104: 189-202
22. Hausenloy DJ, Tsang A, Mocanu MM, Yellon DM (2005) Ischemic preconditioning protects by activating prosurvival kinases at reperfusion. Am J Physiol Heart Circ Physiol 288: H971-H976
23. Heusch G, Boengler K, Schulz R (2008) Cardioprotection: nitric oxide, protein kinases, and mitochondria. Circulation 118: 1915-1919
24. Ito WD, Schaarschmidt S, Klask R, Hansen S, Schafer HJ, Mathey D, Bhakdi S (1997) Infarct size measurement by triphenyltetrazolium chloride staining versus in vivo injection of propidium iodide. J Mol Cell Cardiol 29: 2169-2175
25. Kaheinen P, Pollesello P, Levijoki J, Haikala H (2001) Levosimendan increases diastolic coronary flow in isolated guinea-pig heart by opening ATP-sensitive potassium channels. J Cardiovasc Pharmacol 37: 367-374
26. Kavianipour M, Ronquist G, Wikstrom G, Waldenstrom A (2003) Ischaemic preconditioning alters the energy metabolism and protects the ischaemic myocardium in a stepwise fashion. Acta Physiol Scand 178: 129-137
27. Kersten JR, Montgomery MW, Pagel PS, Warltier DC (2000) Levosimendan, a new positive inotropic drug, decreases myocardial infarct size via activation of K(ATP) channels. Anesth Analg 90: 5-11
28. Kis A, Yellon DM, Baxter GF (2003) Second window of protection following myocardial preconditioning: an essential role for PI3 kinase and p70S6 kinase. J Mol Cell Cardiol 35: 1063-1071
29. Kopustinskiene DM, Pollesello P, Saris NE (2001) Levosimendan is a mitochondrial K(ATP) channel opener. Eur J Pharmacol 428: 311-314
30. Lancaster MK, Cook SJ (1997) The effects of levosimendan on [Ca2+]i in guinea-pig isolated ventricular myocytes. Eur J Pharmacol 339: 97-100
31. Mebazaa A, Barraud D, Welschbillig S (2005) Randomized clinical trials with levosimendan. Am J Cardiol 96: 74G-79G
32. Miura T, Miki T (2008) Limitation of myocardial infarct size in the clinical setting: current status and challenges in translating animal experiments into clinical therapy. Basic Res Cardiol 103: 501-513
33. Mocanu MM, Bell RM, Yellon DM (2002) PI3 kinase and not p42/p44 appears to be implicated in the protection conferred by ischemic preconditioning. J Mol Cell Cardiol 34: 661-668
34. Moiseyev VS, Poder P, Andrejevs N, Ruda MY, Golikov AP, Lazebnik LB, Kobalava ZD, Lehtonen LA, Laine T, Nieminen MS, Lie KI (2002) Safety and efficacy of a novel calcium sensitizer, levosimendan, in patients with left ventricular failure due to an acute myocardial infarction. A randomized, placebo-controlled, double-blind study (RUSSLAN). Eur Heart J 23: 1422-1432
35. Na HS, Kim YI, Yoon YW, Han HC, Nahm SH, Hong SK (1996) Ventricular premature beat-driven intermittent restoration of coronary blood flow reduces the incidence of reperfusion-induced ventricular fibrillation in a cat model of regional ischemia. Am Heart J 132: 78-83
36. Nieminen MS, Akkila J, Hasenfuss G, Kleber FX, Lehtonen LA, Mitrovic V, Nyquist O, Remme WJ (2000) Hemodynamic and neurohumoral effects of continuous infusion of levosimendan in patients with congestive heart failure. J Am Coll Cardiol 36: 1903-1912
37. Nishihara M, Miura T, Miki T, Sakamoto J, Tanno M, Kobayashi H, Ikeda Y, Ohori K, Takahashi A, Shimamoto K (2006) Erythropoietin affords additional cardioprotection to preconditioned hearts by enhanced phosphorylation of glycogen synthase kinase-3 beta. Am J Physiol Heart Circ Physiol 291: H748-H755
38. Nishino Y, Webb IG, Davidson SM, Ahmed AI, Clark JE, Jacquet S, Shah AM, Miura T, Yellon DM, Avkiran M, Marber MS (2008) Glycogen synthase kinase-3 inactivation is not required for ischemic preconditioning or postconditioning in the mouse. Circ Res 103: 307-314
39. O'Connor CM, Gattis WA, Uretsky BF, Adams KF Jr, McNulty SE, Grossman SH, McKenna WJ, Zannad F, Swedberg K, Gheorghiade M, Califf RM (1999) Continuous intravenous dobutamine is associated with an increased risk of death in patients with advanced heart failure: insights from the Flolan International Randomized Survival Trial (FIRST). Am Heart J 138: 78-86
40. Packer M, Carver JR, Rodeheffer RJ, Ivanhoe RJ, DiBianco R, Zeldis SM, Hendrix GH, Bommer WJ, Elkayam U, Kukin ML et al (1991) Effect of oral milrinone on mortality in severe chronic heart failure. The PROMISE Study Research Group. N Engl J Med 325: 1468-1475
41. Pataricza J, Hohn J, Petri A, Balogh A, Papp JG (2000) Comparison of the vasorelaxing effect of cromakalim and the new inodilator, levosimendan, in human isolated portal vein. J Pharm Pharmacol 52: 213-217
42. Piot C, Croisille P, Staat P, Thibault H, Rioufol G, Mewton N, Elbelghiti R, Cung TT, Bonnefoy E, Angoulvant D, Macia C, Raczka F, Sportouch C, Gahide G, Finet G, Andre-Fouet X, Revel D, Kirkorian G, Monassier JP, Derumeaux G, Ovize M (2008) Effect of cyclosporine on reperfusion injury in acute myocardial infarction. N Engl J Med 359: 473-481
43. Raphael J, Rivo J, Gozal Y (2005) Isoflurane-induced myocardial preconditioning is dependent on phosphatidylinositol-3-kinase/ Akt signalling. Br J Anaesth 95: 756-763
44. Rehberg S, Ertmer C, Van Aken H, Lange M, Broking K, Morelli A, Westphal M (2007) Role of levosimendan in intensive care treatment of myocardial insufficiency. Anaesthesin 56: 30-43
45. Rodriguez-Sinovas A, Cabestrero A, Garcia Del Blanco B, Inserte J, Garcia A, Garcia-Dorado D (2009) Intracoronary acid infusion as an alternative to ischemic postconditioning in pigs. Basic Res Cardiol
46. Russ MA, Prondzinsky R, Christoph A, Schlitt A, Buerke U, Soffker G, Lemm H, Swyter M, Wegener N, Winkler M, Carter JM, Reith S, Werdan K, Buerke M (2007) Hemodynamic improvement following levosimendan treatment in patients with acute myocardial infarction and cardiogenic shock. Crit Care Med 35: 2732-2739
47. Salloum FN, Takenoshita Y, Ockaili RA, Daoud VP, Chou E, Yoshida K, Kukreja RC (2007) Sildenafil and vardenafil but not nitroglycerin limit myocardial infarction through opening of mitochondrial K(ATP) channels when administered at reperfusion following ischemia in rabbits. J Mol Cell Cardiol 42: 453-458
48. Schulz R, Post H, Vahlhaus C, Heusch G (1998) Ischemic preconditioning in pigs: a graded phenomenon: its relation to adenosine and bradykinin. Circulation 98: 1022-1029
49. Skyschally A, van Caster P, Boengler K, Gres P, Musiolik J, Schilawa D, Schulz R, Heusch G (2009) Ischemic postconditioning in pigs: no causal role for RISK activation. Circ Res 104: 15-18
50. Skyschally A, van Caster P, Iliodromitis EK, Schulz R, Kremastinos DT, Heusch G (2009) Ischemic postconditioning: experimental models and protocol algorithms. Basic Res Cardiol 104: 469-483
51. Sonntag S, Sundberg S, Lehtonen LA, Kleber FX (2004) The calcium sensitizer levosimendan improves the function of stunned myocardium after percutaneous transluminal coronary angioplasty in acute myocardial ischemia. J Am Coll Cardiol 43: 2177-2182
52. Staat P, Rioufol G, Piot C, Cottin Y, Cung TT, L'Huillier I, Aupetit JF, Bonnefoy E, Finet G, Andre-Fouet X, Ovize M (2005) Postconditioning the human heart. Circulation 112: 2143-2148
53. Stenslokken KO, Rutkovskiy A, Kaljusto ML, Hafstad AD, Larsen TS, Vaage J (2009) Inadvertent phosphorylation of survival kinases in isolated perfused hearts: a word of caution. Basic Res Cardiol 104: 412-423
54. Thibault H, Piot C, Staat P, Bontemps L, Sportouch C, Rioufol G, Cung TT, Bonnefoy E, Angoulvant D, Aupetit JF, Finet G, Andre-Fouet X, Macia JC, Raczka F, Rossi R, Itti R, Kirkorian G, Derumeaux G, Ovize M (2008) Long-term benefit of postconditioning. Circulation 117: 1037-1044
55. Tissier R, Waintraub X, Couvreur N, Gervais M, Bruneval P, Mandet C, Zini R, Enriquez B, Berdeaux A, Ghaleh B (2007) Pharmacological postconditioning with the phytoestrogen genistein. J Mol Cell Cardiol 42: 79-87
56. Tsang A, Hausenloy DJ, Mocanu MM, Yellon DM (2004) Postconditioning: a form of "modified reperfusion" protects the myocardium by activating the phosphatidylinositol 3-kinase-Akt pathway. Circ Res 95: 230-232
57. Ukkonen H, Saraste M, Akkila J, Knuuti J, Karanko M, lida H, Lehikoinen P, Nagren K, Lehtonen L, Voipio-Pulkki LM (2000) Myocardial efficiency during levosimendan infusion in congestive heart failure. Clin Pharmacol Ther 68: 522-531
58. Wagner C, Kloeting I, Strasser RH, Weinbrenner C (2008) Cardioprotection by postconditioning is lost in WOKW rats with metabolic syndrome: role of glycogen synthase kinase 3beta. J Cardiovasc Pharmacol 52: 430-437
59. Weinbrenner C, Nelles M, Herzog N, Sarvary L, Strasser RH (2002) Remote preconditioning by infrarenal occlusion of the aorta protects the heart from infarction: a newly identified non-neuronal but PKC-dependent pathway. Cardiovasc Res 55: 590-601
60. Wolff RA, Chien GL, van Winkle DM (2000) Propidium iodide compares favorably with histology and triphenyl tetrazolium chloride in the assessment of experimentally-induced infarct size. J Mol Cell Cardiol 32: 225-232
61. Yang XM, Liu Y, Liu Y, Tandon N, Kambayashi J, Downey JM, Cohen MV (2009) Attenuation of infarction in cynomolgus monkeys: preconditioning and postconditioning. Basic Res Cardiol
62. Yang XM, Philipp S, Downey JM, Cohen MV (2005) Postconditioning's protection is not dependent on circulating blood factors or cells but involves adenosine receptors and requires PI3-kinase and guanylyl cyclase activation. Basic Res Cardiol 100: 57-63
63. Yang XM, Proctor JB, Cui L, Krieg T, Downey JM, Cohen MV (2004) Multiple, brief coronary occlusions during early reperfusion protect rabbit hearts by targeting cell signaling pathways. J Am Coll Cardiol 44: 1103-1110
64. Yokoshiki H, Katsube Y, Sunagawa M, Sperelakis N (1997) The novel calcium sensitizer levosimendan activates the ATP-sensitive K+ channel in rat ventricular cells. J Pharmacol Exp Ther 283: 375-383
65. Zhao HX, Wang XL, Wang YH, Wu Y, Li XY, Lv XP, Zhao ZQ, Zhao RR, Liu HR (2009) Attenuation of myocardial injury by postconditioning: role of hypoxia inducible factor-1alpha. Basic Res Cardiol